Key terms
About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ABBV news
Yesterday
5:39pm ET
AbbVie (NYSE:ABBV) Sinks as Humira Drug Sees Increased Competition
Yesterday
10:00am ET
AbbVie says Humira downdraft ‘within what was assumed’
Yesterday
9:39am ET
AbbVie sees FY24 revenue approximately $55B, consensus $54.6B
Yesterday
9:36am ET
AbbVie sees Q2 adjusted EPS $3.05-$3.09, consensus $2.81
Yesterday
9:12am ET
AbbVie says Q1 results exceeded expectations
Yesterday
7:42am ET
AbbVie reports Q1 global revenue from immunology portfolio $5.371B, down 3.9%
Yesterday
7:36am ET
AbbVie raises FY24 adjusted EPS view to $11.13-$11.33 from $10.97-$11.17
Yesterday
7:35am ET
AbbVie reports Q1 adjusted EPS $2.31, consensus $2.23
Yesterday
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 26, 2024
Yesterday
5:06am ET
Hold Rating on AbbVie Amid Revenue Decline and Profitability Concerns
Apr 25
8:25pm ET
Notable companies reporting before tomorrow’s open
Apr 25
1:10pm ET
Notable companies reporting before tomorrow’s open
Apr 25
8:04am ET
AbbVie reports ‘positive’ results from LEVEL UP study
Apr 24
4:20am ET
Wall Street Analysts Are Neutral on Top Healthcare Picks
Apr 22
8:27am ET
AbbVie (ABBV) Gets a Buy from Piper Sandler
Apr 22
7:01am ET
Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
Apr 19
5:45am ET
Wells Fargo Reaffirms Their Buy Rating on AbbVie (ABBV)
Apr 18
8:33am ET
AbbVie reports ‘positive’ results from Phase 3 SELECT-GCA study of upadacitinib
Apr 17
3:25am ET
AbbVie (ABBV) Gets a Buy from Barclays
Apr 16
2:02pm ET
Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally
Apr 15
2:30am ET
AbbVie Stock (NYSE:ABBV): Humira Leads Market with 96% Share
Apr 12
7:32am ET
AbbVie presents results from ongoing Phase 3 study of oral atogepant
Apr 08
3:50am ET
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Apr 08
3:31am ET
Analysts Conflicted on These Healthcare Names: AbbVie (ABBV), Universal Health (UHS) and Teladoc (TDOC)
Apr 05
1:36am ET
AbbVie (NYSE:ABBV) Trims EPS Outlook, Stock Drops
Apr 03
7:27am ET
Oppenheimer more bullish on Aldeyra, upgrades to Outperform
Apr 03
5:20am ET
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV) and AbbVie (ABBV)
Apr 02
11:16am ET
AbbVie put volume heavy and directionally bearish
Apr 01
5:58am ET
This Biopharma Stock Outperformed MSTR and SMCI in March 2024
Mar 26
8:24pm ET
AbbVie price target raised to $195 from $185 at Barclays
Mar 25
9:10pm ET
Analysts Offer Insights on Healthcare Companies: Fate Therapeutics (FATE) and AbbVie (ABBV)
No recent press releases are available for ABBV
ABBV Financials
Key terms
Ad Feedback
ABBV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ABBV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
